FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage PR Newswire HOUSTON, Aug. 5, 2026 Granted claims cover Sox9-based conversion of fibroblasts into...
PR Newswire
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate PR Newswire HOUSTON, July 31, 2026 - First...
PR Newswire
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors PR Newswire HOUSTON, July 9, 2026 Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute...
PR Newswire
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire HOUSTON, July 7, 2026 Company...
PR Newswire
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference PR Newswire HOUSTON, June 30, 2026 HOUSTON, June 30, 2026 /PRNewswire...
PR Newswire
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire HOUSTON, June 29, 2026 $3.0 million upfront with up to...
PR Newswire
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire HOUSTON, June 26, 2026 $3.0 million upfront with up to approximately $6.0 million...
PR Newswire
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.read more...
Benzinga
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data...
Yahoo! Finance: News
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interim data expected in Q3 2026.read more...
Benzinga